L&G Pharma Breakthrough UCITS ETF ISIN DE000A2H9VJ3, WKN A2H9VJ

Add to portfolio Watch Compare

Strategy of L&G Pharma Breakthrough UCITS ETF

Investment strategy

The Solactive Biotechnology Breakthrough Value index tracks companies involved in the development and manufacturing of so-called "orphan drugs". Orphan drugs are drugs that target very rare diseases.


Solactive Biotechnology Breakthrough Value (1)

Equity (992) World (179) Health Care (7)


EUR 9.99
7.92 52 weeks low/high 9.99
52 weeks low/high
Buy Sell
Savings plan ready
Show all offers

Risk and fees of L&G Pharma Breakthrough UCITS ETF


EUR 8 m
Fund size
Fund size category


Physical (Sampling)
Legal structure ETF
Strategy risk Long-only
Fund currency USD

Currency risk

Currency unhedged
Volatility 1 year (in EUR) 17.38% Risk category
Inception Date 15 December 2017
Maximum drawdown
since inception (in USD)
Maximum drawdown period 15 Months


0.75% p.a.
Total expense ratio
0.04% Compare 0.98%
Compare (Equity)

Dividend/ Taxes

Distribution policy Accumulating
Distribution frequency -
Fund domicile Ireland
Tax data Bundesanzeiger

Legal structure

Fund Structure -
UCITS compliance Yes
Fund Provider Legal & General (LGIM)
Administrator BNY Mellon Fund Services (Ireland) Designated Activity Company
Investment Advisor GO ETF Management Limited
Custodian Bank BNY Mellon Trust Company (Ireland) Limited
Revision Company KPMG
Fiscal Year End 30 June
Swiss representative State Street Fondsleitung AG
Swiss paying agent State Street Bank International GmbH, München, Zweigniederlassung Zürich

Tax Status

Germany Unkown
Switzerland Unknown
Austria Unknown
UK Unknown
EU Savings Directive -

Replication, swap, securities lending

Indextype Total return index
Swap counterparty -
Collateral manager
Securities lending No
Securities lending counterparty

Performance of L&G Pharma Breakthrough UCITS ETF


1 year: 15.05%
Performance (incl. dividend)
Return in:
YTD 2019 2018 2017 2016
8.40% 14.77% - - -
1 month 3 months 6 months 1 year 3 years
6.65% 22.11% 15.45% 15.05% -

Savings plan offers for the L&G Pharma Breakthrough UCITS ETF

Select your savings amount:

Broker Rating Savings plan offer Brokerage fee More information
EUR 1.00
free of charge
More info
EUR 1.50 + ATC
free of charge
Penalty rate
More info
Show all offers

Description of L&G Pharma Breakthrough UCITS ETF

The L&G Pharma Breakthrough UCITS ETF invests in stocks with focus Health Care, World. The dividends in the fund are reinvested (accumulating).

The total expense ratio amounts to 0.75% p.a.. The fund replicates the performance of the underlying index by buying a selection of the most relevant index constituents (sampling technique). The L&G Pharma Breakthrough UCITS ETF is a very small ETF with 8m Euro assets under management. The ETF is older than 1 year and is domiciled in Ireland.

Look for similar ETFs

— All quotes are 15 minutes delayed stock exchange quotes or NAVs (=daily published by fund provider). Quotes and reference data provided by Xignite, Inc., etfinfo and justETF GmbH. Returns include dividend payments. There is no warranty for completeness, accuracy and correctness for the displayed information.

Track your ETF strategies online